In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target of $138.00. The company’s shares closed yesterday ...

Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of $231.00. The company’s shares closed yesterday at ...

SAN FRANCISCO (Reuters) - Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO ...

Jan 10 (Reuters) - Drugmaker Biogen (BIIB.O), opens new tab will buy all outstanding shares of Sage Therapeutics (SAGE.O), opens new tab that it does not already own for $7.22 apiece, a filing ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's board of directors ...

(Reuters) - Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece, a filing showed on Friday, sending the latter's stock up 34% in ...

SAN FRANCISCO Jan 14 (Reuters) - Biogen (BIIB.O), opens new tab expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business ...

Shares of Biogen Inc. BIIB slid 1.10% to $142.34 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,994.57 and Dow ...

Vanessa Leroy / Bloomberg via Getty Images Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.

Biogen offers $7.22 per share to acquire Sage Therapeutics. Goldman Sachs projects Zurzuvae could reach $700 million in global sales by 2034. Get Pro-Level Earnings Insights Before the Market ...